Real-world Tolerability of Foslevodopa/Foscarbidopa Subcutaneous Infusion in Parkinson’s Disease: Discontinuation Beyond Titration

Levodopa Initiation or Dose Adjustments in TEMPO-4: A 58-Week Open-label Trial of Tavapadon for Treatment of PD

Efficacy and Safety of Dimethyl Fumarate in Friedreich Ataxia: Primary Results From the Phase Two, Randomized, Double-blind, Placebo-controlled DMF-FA-201 Trial

Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA)